Opalescence of an IgG1 Monoclonal Antibody Formulation is Mediated by Ionic Strength and Excipients - Can increase in ionic strength result in higher viscosity? - BioPharm International


Opalescence of an IgG1 Monoclonal Antibody Formulation is Mediated by Ionic Strength and Excipients
Can increase in ionic strength result in higher viscosity?

BioPharm International
Volume 22, Issue 4

Figure 10
A Zimm plot of MAb1 in the formulation containing a buffer and 150 mM NaCl is depicted in Figure 10. PS-80 was removed from the formulation to prevent potential interference from micelles. It was determined that this formulation had a negative second virial coefficient (–4.3 x 10-5 mol mL/g2). The molecular weight calculated for MAb1 was 1.46 x 105 g/mol (146 kDa), which is close to the molecular weight of MAb1, which is 148 kDa.


The purpose of this study was to investigate whether the ionic strength and excipients in the MAb1 formulation were associated with the opalescence observed. We identified that the ionic strength of the MAb1 formulation played a major role in mediating opalescence.

Effects of Ionic Strength

The opalescence of MAb1 was demonstrated to increase with ionic strength. In the MAb1 formulation containing NaCl, opalescence was pronounced (Reference III opalescence standard) whereas in its absence, the solution was clear (Reference I opalescence standard). It was also observed that the apparent hydrodynamic radius of the MAb1 formulation was larger at higher concentrations (20 mg/mL) and lower at more dilute concentrations (1 mg/mL). The reason for the larger particle size at higher concentrations of MAb1 is not known, and will require further investigation.

We explored whether salts other than NaCl had an impact on opalescence. Salts were selected based on their position in the Hofmeister series, and included KCl, MgCl2, KSCN, Na3PO4, CsCl, and Na2SO4.14,15 Opalescence was observed in the presence of all salts tested, and no specific ion effects were observed.

As the concentration of NaCl was increased, the electrostatic shielding becomes saturated and it is possible that interactions between the hydrophobic regions of MAb1 become dominant. An example of electrostatic shielding and enhancement of hydrophobic effects in the presence of NaCl was demonstrated in studies using lysozyme.5,20

There are other examples of the effect of ionic strength on proteins. It was demonstrated that when recombinant factor VIII SQ was placed in a solution containing 100 mM NaCl at pH 7, the solution turned opalescent within the first hour.7 However, after the first hour, the protein precipitated out of solution.7 At higher concentrations of NaCl, the precipitate could be dissolved, and activity was observed to recover.7

The interactions between MAb1 molecules described in these studies were not strong enough to precipitate the MAb. It is not known, however, if the increase in opalescence correlates to molecular self-association of MAb1 molecules. Sukumar and colleagues have attributed opalescence of an IgG1 formulation to Rayleigh scatter and indicated that opalescence is not caused by noncovalent association.4

Effects of Excipients

PS-80 has been widely used in liquid parenteral formulations to reduce aggregation caused by surface interactions, to prevent denaturation at the air–liquid interface, and to reduce agitation and temperature-induced aggregation.12,21 In this study, it was demonstrated that PS-80 was able to reduce the opalescence of the MAb1 formulation containing 150 mM NaCl. It is possible that PS-80 partially disrupted the hydrophobic–hydrophobic interactions that are dominant following the initial shielding of electrostatic charges.

blog comments powered by Disqus



European Commission Approves RoACTEMRA for Treatment of RA
September 9, 2014
PDA Announces Technical Report on Drug Shortages
September 9, 2014
Infinity and AbbVie Collaborate to Develop Oncology Drug
September 5, 2014
Merck KGaA Breaks Ground on Facility in China
September 5, 2014
DPT Laboratories Acquires Media Pharmaceuticals' Lakewood Facilities
September 5, 2014
Author Guidelines
Source: BioPharm International,
Click here